Gene therapeutics in Sjögren’s syndrome

Bibliography

• VENABLES PJ: Sjogren's syndrome. Best Pract. Res. Clin. Rheumatol (2004) 18(3):313–329.
   PubMedGoogle Scholar
• JONSSON R, BOWMAN S, GORDON TP: Sjogren's syndrome. In: Arthritis and Allied Conditions —A Textbook of Rheumatology. Koopman WJ, Moreland LW (Eds), Lippincott, Williams & Wilkins, Philadelphia, (2005):1681–1705.
   Google Scholar
• VITALI C, BOMBARDIERI S, JONSSON R et al: Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann. Rheum. Dis. (2002) 61(6):554–558.
   PubMed Web of Science ®Google Scholar
• RHODES G, CARSON DA, VALBRACHT J, HOUGHTEN R, VAUGHAN JH: Human immune responses to synthetic peptides from the Epstein-Barr nuclear antigen. J. Immunol. (1985) 134(1):211–216.
   PubMed Web of Science ®Google Scholar
• PFLUGFELDER SC, TSENG SC, PEPOSE JS et al.: Epstein-Barr virus infection and immunologic dysfunction in patients with aqueous tear deficiency. Ophthalmology (1990) 97(3):313–323.
   PubMed Web of Science ®Google Scholar
• SAITO I, SERVENIUS B, COMPTON T, FOX RI: Detection of Epstein-Barr virus DNA by polymerase chain reaction in blood and tissue biopsies from patients with Sjogren's syndrome. J. Exp. Med. (1989) 169(6):2191–2198.
   PubMed Web of Science ®Google Scholar
• BAGMAN S, BERRA A, STERIN-BORDA L, BORDA E: Muscarinic acetylcholine receptor antibodies as a new marker of dry eye Sjogren syndrome. Invest. Ophthalmol Vs. (2001) 42(2):321–327.
   PubMed Web of Science ®Google Scholar
• BAGMAN S, PEREZ LEIROS C, STERIN-BORDA Let al.: Autoantibodies against lacrimal gland M3 muscarinic acetylcholine receptors in patients with primary Sjogren's syndrome. Invest. Ophthalmol Vis. Sci. (1998) 39(1):151–156.
   Google Scholar
• BAGMAN S, STERIN-BORDA L, CAMUSSO JJ et al.: Circulating antibodies against rat parotid gland M3 muscarinic receptors in primary Sjogren's syndrome. Clin. Exp. Immunol (1996) 104(3):454–459.
   PubMed Web of Science ®Google Scholar
• •The first paper to indicate functional autoantibodies in SS.
   Google Scholar
• BEROUKAS D, GOODFELLOW R, HISCOCK J et al.: Up-regulation of M3-muscarinic receptors in labial salivary gland acini in primary Sjogren's syndrome. Lab. Invest. (2002) 82(2):203–210.
   PubMed Web of Science ®Google Scholar
• GAO J, CHA S, JONSSON R, OPALKO J, PECK AB: Detection of anti-type 3 muscarinic acetylcholine receptor autoantibodies in the sera of Sjogren's syndrome patients by use of a transfected cell line assay. Arthritis Rheum. (2004) 50(8):2615–2621.
   PubMed Web of Science ®Google Scholar
• TSUBOTA K, HIRAI S, KING LS, AGRE P, ISHIDA N: Defective cellular trafficking of lacrimal gland aquaporin-5 in Sjogren's syndrome. Lancet (2001) 357(9257):688–689.
   PubMed Web of Science ®Google Scholar
• •One of a series of reports describing the role of AQP-5 in SS.
   Google Scholar
• BEROUKAS D, HISCOCK J, JONSSON R, WATERMAN SA, GORDON TP: Subcellular distribution of aquaporin 5 in salivary glands in primary Sjogren's syndrome. Lancet (2001) 358(9296):1875–1876.
   PubMed Web of Science ®Google Scholar
• •One of a series of reports describing the role of AQP-5 in SS.
   Google Scholar
• STEINFELD S, COGAN E, KING LS et al.: Abnormal distribution of aquaporin-5 water channel protein in salivary glands from Sjogren's syndrome patients. Lab. Invest. (2001) 81(2):143–148.
   PubMed Web of Science ®Google Scholar
• •One of a series of reports describing the role of AQP-5 in SS.
   Google Scholar
• KRANE CM, MELVIN JE, NGUYEN HV et al.: Salivary acinar cells from aquaporin 5-deficient mice have decreased membrane water permeability and altered cell volume regulation. J. Biol. Chem. (2001) 276(26):23413–23420.
   PubMed Web of Science ®Google Scholar
• LISCH K: Ober hereditarishes vorkommen des mit keratoconjunctivitis sicca verbundenen Sjogrenschen symptomenkomplexen. Arch. Augenheilkd. (1937) 110:357.
   Google Scholar
• REVEILLE JD, WILSON RW, PROVOST TT, BIAS WB, ARNETT FC: Primary Sjogren's syndrome and other autoimmune diseases in families. Prevalence and immunogenetic studies in six kindreds. Ann. Intern. Med. (1984) 101(6):748–756.
   PubMed Web of Science ®Google Scholar
• ••A detailed description of the role ofheredity in SS.
   Google Scholar
• BECKER KG, SIMON RM, BAILEY-WILSON JE et al.: Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc. Natl Acad. Sci. USA (1998) 95(17):9979–9984.
   PubMed Web of Science ®Google Scholar
• BOLSTAD Al, JONSSON R: Genetic aspects of Sjogren's syndrome. Arthritis Res. (2002) 4(6):353–359.
   PubMedGoogle Scholar
• BOLSTAD Al, HAGA HJ, WASSMUTH R, JONSSON R: Monozygotic twins with primary Sjogren's syndrome. j Rheumatol (2000) 27(9):2264–2266.
   PubMed Web of Science ®Google Scholar
• BOLSTAD AI, HAGA HJ, JOHANNESEN A, THOMMASSEN E, JONSSON R: Norwegian families multiplex for primary Sjogren's sydrome. In: The 100-year Anniversary of Henrik Sjägren. Eriksson P, Jonsson R (Eds), Hygiea, Jönkoping, Sweden (1999):98.
   Google Scholar
• BOLSTAD Al, WARGELIUS A, NAKKEN B, HAGA HJ, JONSSON R: Fas and Fas ligand gene polymorphisms in primary Sjogren's syndrome./ Rheumatol (2000) 27(10):2397–2405.
   PubMed Web of Science ®Google Scholar
• BOLSTAD Al, WASSMUTH R, HAGA HJ, JONSSON R: HLA markers and clinical characteristics in Caucasians with primary Sjogren's syndrome. Rheumatol (2001) 28(7):1554–1562.
   Web of Science ®Google Scholar
• NAKKEN B, JONSSON R, BOLSTAD Al: Polymorphisms of the Ro52 gene associated with anti-Ro 52-kd autoantibodies in patients with primary Sjogren's syndrome. Arthritis Rheum. (2001) 44(3):638–646.
   PubMed Web of Science ®Google Scholar
• GUGGENBUHL P, VEILLARD E, QUELVENEC E et al.: Analysis of TNFalpha microsatellites in 35 patients with primary Sjogren's syndrome. Joint Bone Spine (2000) 67(4):290–295.
   PubMed Web of Science ®Google Scholar
• HULKKONEN J, PERTOVAARA M, ANTONEN J et al.: Genetic association between interleukin-10 promoter region polymorphisms and primary Sjogren's syndrome. Arthritis Rheum. (2001) 44(1):176–179.
   PubMed Web of Science ®Google Scholar
• HULKKONEN J, VILPO J, VILPO L, KOSKI T, HURME M: Interleukin-1 beta, interleukin-1 receptor antagonist and interleukin-6 plasma levels and cytokine gene polymorphisms in chronic lymphocytic leukemia: correlation with prognostic parameters. Haematologica (2000) 85(6):600–606.
   PubMedGoogle Scholar
• PERRIER S, COUSSEDIERE C, DUBOST JJ, ALBUISSON E, SAUVEZIE B: IL-1 receptor antagonist (IL-1RA) gene polymorphism in Sjogren's syndrome and rheumatoid arthritis. Clin. Immunol Immunopathol (1998) 87(3):309–313.
   PubMedGoogle Scholar
• RISCH NJ: Searching for genetic determinants in the new millennium. Nature (2000) 405(6788):847–856.
   PubMed Web of Science ®Google Scholar
• CHERNAJOVSKY Y, GOULD DJ, PODHAJCER OL: Gene therapy for autoimmune diseases: quo vadis? Nat. Rev. Immunol (2004) 4(10):800–811.
   Google Scholar
• HJELMERVIK TO, PETERSEN K, JONASSEN I, JONSSON R, BOLSTAD Al: Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects. Arthritis Rheum. (2005) 52(5):1534–1544.
   PubMed Web of Science ®Google Scholar
• ••First global gene expression analysis ofsalivary gland tissue in SS.
   Google Scholar
• MITSIAS DI, TZIOUFAS AG, VEIOPOULOU C et al.: The Thl/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjogren's syndrome. Clin. Exp. Immunol. (2002) 128(3):562–568.
   PubMed Web of Science ®Google Scholar
• JONSSON MV, SZODORAY P, JELLESTAD S, JONSSON R, SKARSTEIN K: Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogren's syndrome. Clin. Immunol (2005) 25:(In Press).
   Google Scholar
• IOANNIDIS JP, VASSILIOU VA, MOUTSOPOULOS HM: Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthritis Rheum. (2002) 46(3):741–747.
   PubMed Web of Science ®Google Scholar
• ATKINSON JC, BAUM BJ: Salivary enhancement: current status and future therapies. J. Dent. Educ. (2001) 65(10):1096–1101.
   PubMedGoogle Scholar
• MARIETTE X, RAVAUD P, STEINFELD S et al.: Inefficacy of infliximab in primary Sjiigren's syndrome: results of the randomized, controlled trial of remicade in primary Sjögren's syndrome (TRIPSS). Arthritis Rheum. (2004) 50(4):1270–1276.
   PubMed Web of Science ®Google Scholar
• FURLAN R, BUTTI E, PLUCHINO S, MARTINO G: Gene therapy for autoimmune diseases. Curr. Opin. MoL Ther. (2004) 6(5):525–536.
   PubMed Web of Science ®Google Scholar
• KYTTARIS VC, JUANG YT, TSOKOS GC: Gene therapy in systemic lupus erythematosus. Lupus (2004) 13(5):353–358.
   PubMed Web of Science ®Google Scholar
• BAKER D, HANKEY DJ: Gene therapy in autoimmune, demyelinating disease of the central nervous system. Gene Ther. (2003) 10(14844–853.
   Google Scholar
• BOTTINO R, LEMARCHAND P, TRUCCO M, GIANNOUKAKIS N: Gene- and cell-based therapeutics for type I diabetes mellitus. Gene They. (2003) 10(10):875–889.
   PubMed Web of Science ®Google Scholar
• HART DA, KYDD AS, FRANK CB, HILDEBRAND KA: Tissue repair in rheumatoid arthritis: challenges and opportunities in the face of a systemic inflammatory disease. Best Pract. Res. Clin. Rheumatol (2004) 18(2):187–202.
   PubMed Web of Science ®Google Scholar
• TIAN C, BAGLEY J, CRETIN N et al.: Prevention of type 1 diabetes by gene therapy. J. Clin. Invest. (2004) 114(7):969–978.
   PubMed Web of Science ®Google Scholar
• GIANNOUKAKIS N, TRUCCO M: Current status and prospects for gene and cell therapeutics for type 1 diabetes mellitus. Rev. Endocr. Metab. Disord. (2003) 4(4):369–380.
   PubMed Web of Science ®Google Scholar
• FLECK M, ZHANG HG, KERN ER et al.: Treatment of chronic sialadenitis in a murine model of Sjögren's syndrome by local fasL gene transfer. Arthritis Rheum. (2001) 44(4):964–973.
   PubMed Web of Science ®Google Scholar
• •Experimental local gene therapy targeting apoptosis regulation in murine SS.
   Google Scholar
• VITOLO JM, BAUM BJ: The use of gene transfer for the protection and repair of salivary glands. Oral Dis. (2002) 8(0183–191.
   PubMed Web of Science ®Google Scholar
• SLAVIN AJ, TARNER IH, NAKAJIMA A et al.: Adoptive cellular gene therapy of autoimmune disease. Autoimmun. Rev. (2002) 1(4):213–219.
   PubMedGoogle Scholar
• RATKO TA, CUMMINGS JP, BLEBEA J, MATUSZEWSKI KA: Clinical gene therapy for nonmalignant disease. Am. J. Med. (2003) 115(7):560–569.
   PubMed Web of Science ®Google Scholar
• LOESSNER H, WEISS S: Bacteria-mediated DNA transfer in gene therapy and vaccination. Expert Opin. Biol. Ther. (2004) 4(2):157–168.
   PubMed Web of Science ®Google Scholar
• LEE TW, MATTHEWS DA, BLAIR GE: Novel molecular approaches to cystic fibrosis gene therapy. Biochem. J. (2005) 387(Pt 1):1–15.
   PubMedGoogle Scholar
• SMAGLIK P: Tighter watch urged on adenoviral vectors.. .with proposal to report all 'adverse events'. Nature (1999) 402(6763):707.
   Google Scholar
• DRISKELL RA, ENGELHARDT JF: Current status of gene therapy for inherited lung diseases. Annu. Rev. Physiol (2003) 65:585–612.
   PubMed Web of Science ®Google Scholar
• CAVAZZANA-CALVO M, HACEIN-BEY S, DE SAINT BASILE G et al.: Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science (2000) 288(5466):669–672.
   Google Scholar
• YAMANO S, BAUM BJ: Prospects for gene-based immunopharmacology in salivary glands. Jpn. j Pharmacol (2000) 82(4):281–286.
   PubMedGoogle Scholar
• BAUM BJ, VOUTETAKIS A. WANG J: Salivary glands: novel target sites for gene therapeutics. Trends Mol. Med. (2004) 10(12):585–590.
   PubMed Web of Science ®Google Scholar
• BAUM BJ, GOLDSMITH CM, HOQUE AT et al.: Salivary glands as a model for craniofacial applications of gene transfer. Int. J. Oral Maxillofac. Surg. (2000) 29(3):163–166.
   PubMed Web of Science ®Google Scholar
• KAGAMI H, ATKINSON JC, MICHALEK SM et al.: Repetitive adenovirus administration to the parotid gland: role of immunological barriers and induction of oral tolerance. Hum. Gene Ther. (1998) 9(3):305–313.
   PubMed Web of Science ®Google Scholar
• •Repetitive administration of the vector induces tolerance.
   Google Scholar
• KAWAGUCHI Y: A gene therapy or purified CTLA4IgG treatment of experimental allergic encephalomyelitis. Hokkaido Igaku Zasshi (1999) 74(6):467–475.
   PubMedGoogle Scholar
• QUATTROCCHI E, DALLMAN MJ, FELDMANN M: Adenovirus-mediated gene transfer of CTLA-41g fusion protein in the suppression of experimental autoimmune arthritis. Arthritis Rheum. (2000) 43(8):1688–1697.
   PubMed Web of Science ®Google Scholar
• BOLSTAD Al, EIKEN HG, ROSENLUND B, ALARCON-RIQUELME ME, JONSSON R: Increased salivary gland tissue expression of Fas, Fas ligand, cytotoxic T lymphocyte-associated antigen 4, and programmed cell death 1 in primary Sjögren's syndrome. Arthritis Rheum. (2003) 48(1):174–185.
   PubMed Web of Science ®Google Scholar
• KURIEN BT, ASFA S, LI C et al.: Induction of oral tolerance in experimental Sjögren's syndrome autoimmunity. Scand. Immunol (2005) 61(5):418–425.
   PubMed Web of Science ®Google Scholar
• MASTRANGELI A, O'CONNELL B, ALADIB Wet al.: Direct in vivo adenovirus-mediated gene transfer to salivary glands. Am. J. Physiol. (1994) 266(6 Pt 1):G1146–G1155.
   Google Scholar
• •An early description of gene transfer to salivary glands.
   Google Scholar
• VOUTETAKIS A, KOK MR, ZHENG C et al.: Reengineered salivary glands are stable endogenous bioreactors for systemic gene therapeutics. Proc. Natl Acad. Sci. USA (2004) 101(9):3053–3058.
   PubMed Web of Science ®Google Scholar
• ••Evidence for systemic gene therapy afterlocal glandular delivery.
   Google Scholar
• KAGAMI H, O& CONNELL BC, BAUM BJ: Evidence for the systemic delivery of a transgene product from salivary glands. Hum. Gene They. (1996) 7(17):2177–2184.
   PubMed Web of Science ®Google Scholar
• ZUFFEREY R, AEBISCHER P: Salivary glands and gene therapy: the mouth waters. Gene They. (2004) 11(19):1425–1426.
   PubMed Web of Science ®Google Scholar
• ZHU Z, STEVENSON D, SCHECHTER JE et al.: Prophylactic effect of IL-10 gene transfer on induced autoimmune dacryoadenitis. Invest. Ophthalmol. Vis. Sci. (2004) 45(5):1375–1381.
   PubMed Web of Science ®Google Scholar
• BANIN E, OBOLENSKY A, PIONTEK E et al.: Gene delivery by viral vectors in primary cultures of lacrimal gland tissue. Invest. Ophthalmol. Vis. Sci. (2003) 44(4):1529–1533.
   PubMed Web of Science ®Google Scholar
• DELALEU N, JONSSON MV JONSSON R: Disease mechanism of Sjögren's syndrome. Drug Discov. Today: Dis. Mech. (2004) 1(3):329–336.
   Google Scholar
• DOUGLAS MR, MORRISON KE, SALMON M, BUCKLEY CD: Why does inflammation persist: a dominant role for the stromal microenvironment? Expert Rev. Mol Med. (2002) 2002:1–18.
   Google Scholar
• SZODORAY P, ALEX P, BRUN JG, CENTOLA M, JONSSON R: Circulating cytokines in primary Sjogren's syndrome determined by a multiplex cytokine array system. Scand. j Immunol (2004) 59(0:592–599.
   PubMedGoogle Scholar
• YAIVIANO S, HUANG LY, DING C et al.:Recombinant adeno-associated virus serotype 2 vectors mediate stable interleukin 10 secretion from salivary glands into the bloodstream. Hum. Gene Ther. (2002) 13(2):287–298.
   PubMed Web of Science ®Google Scholar
• KOK MR, YAIVIANO S, LODDE BM et al.: Local adeno-associated virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sjogren's syndrome. Hum. Gene Ther. (2003) 14(17):1605–1618.
   PubMed Web of Science ®Google Scholar
• OHLSSON M, SKARSTEIN K, BOLSTAD M, JOHANNESSEN AC, JONSSON R: Fas-induced apoptosis is a rare event in Sjogren's syndrome. Lab. Invest. (2001) 81(1):95–105.
   PubMed Web of Science ®Google Scholar
• BRATTON DL, HENSON PM: Autoimmunity and apoptosis: refusing to go quietly. Nat. Med. (2005) 11(1):26–27.
   PubMed Web of Science ®Google Scholar
• CHANG MK, BINDER CJ, MILLER YT et al.: Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory. J. Exp. Med. (2004) 200(11):1359–1370.
   PubMed Web of Science ®Google Scholar
• OHLSSON M, JONSSON R, BROKSTAD K: Subcellular redistribution and surface exposure of the Ro52, Ro60 and La48 autoantigen during apoptosis in human ductal epithelial cells: a possible mechanism in the pathogenesis of Sjogren's syndrome. Scand. j Immunol (2002) 56(5):456–469.
   PubMed Web of Science ®Google Scholar
• DELPORTE C, O& CONNELL BC, HEX et al.: Increased fluid secretion after adenoviral-mediated transfer of the aquaporin-1 cDNA to irradiated rat salivary glands. Proc. Natl Acad. Sci. USA (1997) 94(7):3268–3273.
   Google Scholar
• •Experimental targeting of AQP-1 increases fluid secretion in salivary glands.
   Google Scholar
• BEROUKAS D, HISCOCK J, GANNON BJ et al.: Selective down-regulation of aquaporin-1 in salivary glands in primary Sjogren's syndrome. Lab. Invest. (2002) 82(1 0:1547–1552.
   Google Scholar
• •Immunomorphological evidence for low levels of AQP-1 in SS.
   Google Scholar
• BAUM BJ, KOK M, TRAN SD, YAMANO S: The impact of gene therapy on dentistry: a revisiting after six years. J. Am. Dent. Assoc. (2002) 133(1):35–44.
   PubMed Web of Science ®Google Scholar
• O'CONNELL AC, BACCAGLINI L, FOX PC et al.: Safety and efficacy of adenovirus-mediated transfer of the human aquaporin-1 cDNA to irradiated parotid glands of non-human primates. Cancer Gene Ther. (1999) 6(6):505–513.
   Google Scholar
• DELPORTE C, CHEN ZJ, BAUM BJ: Aquaporin 1 expression during the cell cycle in AS cells. Biochem. Biophys. Res. Commun. (1996) 228(2):223–228.
   PubMed Web of Science ®Google Scholar
• MOTEGI K, AZUMA M, TAMATANI T, ASHIDA Y, SATO M: Expression of aquaporin-5 in and fluid secretion from immortalized human salivary gland ductal cells by treatment with 5-aza-2'-deoxycytidine: a possibility for improvement of xerostomia in patients with Sjogren's syndrome. Lab. Invest. (2005) 85(3):342–353.
   PubMed Web of Science ®Google Scholar
• O'CONNELL BC, XU T, WALSH TJ et al.: Transfer of a gene encoding the anticandidal protein histatin 3 to salivary glands. Hum. Gene Ther. (1996) 7(18):2255–2261.
   Google Scholar